Vienna, VA
Peptide Therapy clinics in Vienna
Vienna has a Northern Virginia Beltway professional demographic, and peptide therapy has grown into a visible slice of the local wellness market. The clinics we track across Tysons Corner, Oakton, and the Town of Vienna range from physician-led longevity practices to medspa-adjacent wellness offices offering sermorelin blends and growth hormone peptides. Most local prescribers have training or admitting privileges within the Inova Fairfax and Virginia Hospital Center network. The scene here skews toward clinics serving federal executives, defense contractors, and Tysons finance professionals. The regulatory landscape shifted sharply in 2023 and 2024 when the FDA placed several widely prescribed peptides on its Category 2 bulk substances list, restricting which ingredients compounding pharmacies could legally source. That changed access overnight for BPC-157, CJC-1295, ipamorelin, and thymosin beta-4. Sermorelin and tesamorelin remain FDA-approved for specific indications, and reputable Vienna clinics now draw a clearer line between approved peptides and off-label research compounds than they did two years ago.
Everest Health Partners
- PRP Therapy
- Hyperbaric Oxygen Therapy (HBOT)
- Arthritis Treatment
- Peptide Therapy
- Hormone Replacement Therapy (HRT)
Artiusmedical
- PRP Therapy
- Ozone Therapy
- IV Therapy
- Arthritis Treatment
- Lyme Disease Treatment
Vita Fusion Doctors
- NAD IV Therapy
- Vitamin IV Therapy
- IV Therapy
- Laser Therapy (LLLT)
- IV Hydration
Proactive Wellness Centers
- Vitamin IV Therapy
- PRP Therapy
- Shockwave Therapy
- IV Therapy
- Arthritis Treatment
Vita Fusion Doctors
- NAD IV Therapy
- Vitamin IV Therapy
- IV Therapy
- Laser Therapy (LLLT)
- IV Hydration
Regulatory context
A note on Virginia's peptide therapy rules.
Most research peptides used in regenerative medicine (BPC-157, TB-500, CJC-1295, ipamorelin) are not FDA-approved drugs. Sermorelin and tesamorelin hold FDA approvals for specific indications. The FDA placed several peptides into Category 2 on its Bulk Drug Substances Nominated for Use in Compounding list during 2023 and 2024, restricting 503A pharmacy sourcing. Section 503A covers traditional patient-specific compounding; Section 503B covers FDA-registered outsourcing facilities held to cGMP.
-
Code of Virginia Title 54.1 Chapter 33 (Pharmacy)
Governs pharmacy licensure and compounding under the Virginia Board of Pharmacy. -
Code of Virginia Title 54.1 Chapter 29 (Medicine and Other Healing Arts)
Regulates physician prescribing and delegation. -
18 Virginia Administrative Code 110-20
Implements pharmacy compounding rules consistent with USP 795 and 797.
The Virginia Board of Pharmacy inspects compounding pharmacies for USP compliance. Non-resident pharmacies shipping peptides into Virginia must hold a current non-resident permit. The Board publishes disciplinary actions. Virginia coordinates with DC and Maryland regulators for cross-border clinic operations.